BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32393842)

  • 1. Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy.
    Nieto JC; Roldán E; Jiménez I; Fox L; Carabia J; Ortí G; Puigdefàbregas L; Gallur L; Iacoboni G; Raheja P; Pérez A; Bobillo S; Salamero O; Palacio C; Valcárcel D; Crespo M; Bosch F; Barba P
    Leukemia; 2020 Dec; 34(12):3420-3425. PubMed ID: 32393842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Infections and Delayed CD4
    Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
    Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
    Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C
    J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graft-versus-tumor effect of post-transplant cyclophosphamide-based allogeneic hematopoietic cell transplantation.
    Nakamae H
    Front Immunol; 2024; 15():1403936. PubMed ID: 38903503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.
    Nunes NS; Kanakry CG
    Front Immunol; 2019; 10():2668. PubMed ID: 31849930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study.
    Ito A; Kim SW; Matsuoka KI; Kawakita T; Tanaka T; Inamoto Y; Toubai T; Fujiwara SI; Fukaya M; Kondo T; Sugita J; Nara M; Katsuoka Y; Imai Y; Nakazawa H; Kawashima I; Sakai R; Ishii A; Onizuka M; Takemura T; Terakura S; Iida H; Nakamae M; Higuchi K; Tamura S; Yoshioka S; Togitani K; Kawano N; Suzuki R; Suzumiya J; Izutsu K; Teshima T; Fukuda T
    Int J Hematol; 2020 Nov; 112(5):674-689. PubMed ID: 32748216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial Activation and Stress Index in adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based prophylaxis.
    Escribano-Serrat S; Rodríguez-Lobato LG; Charry P; Martínez-Cibrian N; Suárez-Lledó M; Rivero A; Moreno-Castaño AB; Solano MT; Arcarons J; Nomdedeu M; Cid J; Lozano M; Pedraza A; Rosiñol L; Esteve J; Urbano-Ispizua Á; Palomo M; Fernández-Avilés F; Martínez C; Díaz-Ricart M; Carreras E; Rovira M; Salas MQ
    Cytotherapy; 2024 Jan; 26(1):73-80. PubMed ID: 37952139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation.
    Pasic I; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Mattsson J; Michelis FV
    Ann Hematol; 2020 Jun; 99(6):1377-1387. PubMed ID: 32382774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sigle Agent of Posttransplant Cyclophosphamide Without Calcineurin Inhibitor Controls Severity of Experimental Chronic GVHD.
    Saeki K; Fujiwara H; Seike K; Kuroi T; Nishimori H; Tanaka T; Matsuoka KI; Fujii N; Maeda Y
    Acta Med Okayama; 2024 Apr; 78(2):123-134. PubMed ID: 38688830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
    Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4
    Hadjis AD; Nunes NS; Khan SM; Fletcher RE; Pohl AP; Venzon DJ; Eckhaus MA; Kanakry CG
    Front Immunol; 2022; 13():796349. PubMed ID: 35242129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.
    Cieri N; Greco R; Crucitti L; Morelli M; Giglio F; Levati G; Assanelli A; Carrabba MG; Bellio L; Milani R; Lorentino F; Stanghellini MT; De Freitas T; Marktel S; Bernardi M; Corti C; Vago L; Bonini C; Ciceri F; Peccatori J
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1506-14. PubMed ID: 26001696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
    Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
    Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects.
    Patterson MT; Khan SM; Nunes NS; Fletcher RE; Bian J; Hadjis AD; Eckhaus MA; Mendu SK; de Paula Pohl A; Venzon DJ; Choo-Wosoba H; Ishii K; Qin H; Fry TJ; Cam M; Kanakry CG
    Blood; 2023 Feb; 141(6):659-672. PubMed ID: 36201744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide.
    Schoch LK; Cooke KR; Wagner-Johnston ND; Gojo I; Swinnen LJ; Imus P; Fuchs EJ; Levis M; Ambinder RF; Jones RJ; Gladstone DE
    Blood Adv; 2018 Sep; 2(17):2226-2229. PubMed ID: 30190282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
    Khaled SK; Palmer JM; Herzog J; Stiller T; Tsai NC; Senitzer D; Liu X; Thomas SH; Shayani S; Weitzel J; Forman SJ; Nakamura R
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):268-276. PubMed ID: 26325438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-transplant cyclophosphamide versus antithymocyte globulin in allogeneic hematopoietic cell transplantation: a meta-analysis.
    Gao F; Zhang J; Hu J; Lin L; Xu Y
    Ann Hematol; 2021 Feb; 100(2):529-540. PubMed ID: 33420575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of allogeneic hematopoietic stem cell transplantation with high-dose cyclophosphamide-induced immune tolerance for severe aplastic anemia.
    Guo Z; Gao HY; Zhang TY; Liu XD; Yang K; Lou JX; He XP; Zhang Y; Chen P; Chen HR
    Int J Hematol; 2016 Dec; 104(6):720-728. PubMed ID: 27709450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.